<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03618225</url>
  </required_header>
  <id_info>
    <org_study_id>IORG0006563</org_study_id>
    <nct_id>NCT03618225</nct_id>
  </id_info>
  <brief_title>Duloxetine Role in Reducing Opioid Consumption After Thoracotomy</brief_title>
  <official_title>Duloxetine Role in Reducing Opioid Consumption After Thoracotomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 60 patients scheduled for thoracotomy with the aim of excision of pleural or lung
      cancer, will be randomized by the use of a computer-generated table of random numbers to
      receive duloxetine 60 mg orally 2 hours before the surgical procedure and at 24 hours after
      the surgical procedure or a placebo pill following the same time schedule.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 15, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total dose of morphine needed to treat postoperative pain</measure>
    <time_frame>48 hours</time_frame>
    <description>Total dose of morphine needed to treat postoperative pain over 48 hours of study period</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Post-thoracotomy Pain</condition>
  <arm_group>
    <arm_group_label>duloxetine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>duloxetine 60 mg orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo pill group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo pill orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Duloxetine 60mg</intervention_name>
    <description>duloxetine 60 mg orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure</description>
    <arm_group_label>duloxetine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo pill</intervention_name>
    <description>placebo pill orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure</description>
    <arm_group_label>placebo pill group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  ASA I, II, and III patients scheduled for thoracotomy for pleural or lung cancer
             resection.

          -  Age above 18 years &amp; less than 65 years.

          -  Adequate coagulation function within 30 days of surgery, defined as platelet count
             100,000/mL or more, INR≤ 1.5, and partial thromboplastin time ≤40 seconds.

        Exclusion criteria:

          -  Allergy to duloxetine or to local anesthetics.

          -  Patients with educational, psychiatric (untreated or poorly controlled schizophrenia,
             major depression, or bipolar disorder), or communication (language) barriers that
             would prevent understanding of the informed consent &amp; preclude accurate assessment of
             postoperative pain and/or ability to answer questions about pain.

          -  Patients with severe renal and/or liver disease.

          -  History of chronic pain, long term narcotic use and/or antidepressants.

          -  Reasons for exclusion after randomization will be protocol violations or patient
             request.

          -  Fever, evidence of infection, or other coexisting medical conditions that would
             preclude epidural placement.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ahmed Othman, MD</last_name>
    <phone>00201005098394</phone>
    <email>ahmadhothman@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Institute, Cairo University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ekramy Mansour, MD</last_name>
      <phone>00201224642810</phone>
      <email>ekrameymansoure@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 14, 2018</study_first_submitted>
  <study_first_submitted_qc>August 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2018</study_first_posted>
  <last_update_submitted>January 11, 2020</last_update_submitted>
  <last_update_submitted_qc>January 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Ahmed H Othman</investigator_full_name>
    <investigator_title>Assisstant professor of Anesthesia ICU and pain Relief</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

